Premium Content Preview | 5 Compelling Reasons to Reevaluate Your Test Results Process
In this eBrief we look at why increasing the efficiency of critical test results management (CTRM) is of vitalimportance for your organization and your patients.
Potential Impact of Poorly Handled Test Results
THE FIVE REASONS:
PATIENT CARE MAY BE SUFFERING
Test results can mean everything when people are in the hospital and worrying about what’s happening to them. Every minute counts when it comes to having tests interpreted and the results sent to the ordering physician. In the case of critical lab or radiology results, the faster the results are relayed, the faster the treatment can begin. Even for normal results, quick delivery can give peace of mind, or perhaps help doctors rule out several possible problems in their efforts to diagnose a condition.
Download for all 5 reasons to optimize your test results process
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Mental Health Comorbidities Affect Uptravi Prescribing for PAH
October 23rd 2024New real-world data suggest that physicians are cautious about prescribing the prostacyclin-receptor agonist Uptravi (selexipag) to pulmonary arterial hypertension (PAH) patients with mental health conditions when evidence suggests that it is best to take a proactive approach to treating PAH.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
High-Dose Eylea Shows Unique Properties in nAMD and DME | AAO 2024
October 22nd 2024A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks to as long as 20 weeks for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Read More
